Professor Chas Bountra joins Genomics plc’s Scientific Advisory Board

Press release



Oxford, UK, 28 July 2016. We are pleased to announce the appointment of Professor Chas Bountra to Genomics plc’s Scientific Advisory Board.

Professor Bountra is Chief Scientist at the Structural Genomics Consortium – a group of scientists focussed on using the latest genetic insights to identify new disease pathways and ultimately new targets for drug discovery. This scientific project is catalysed through ‘open’ collaborations with eight global pharmaceutical companies, several hundred academic labs, many patient groups and a number of SMEs, across the world. Within the University of Oxford, he is also Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and an Associate Member of the Department of Pharmacology, and he holds the post of Visiting Professor in Neuroscience and Mental Health at Imperial College, London.

Professor Bountra has served on numerous Scientific Advisory Boards (including Spinifex, Grunenthal, Takeda, Caddick, IMI EPAD, UK Dementia Discovery Fund), and on several charitable, government and VC translational funding committees (including Wellcome Trust Seeding Drug Discovery). Prior to his return to Oxford, Professor Bountra was Vice President and Head of Biology at GlaxoSmithKline. He was involved in the identification of more than 40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases, several of which generated positive clinical POCs, progressed into late stage development and one of which was marketed.